Replies to post #202203 on Biotech Values

[biocqr]

SRPT > Third time the charm? Analyst says a marketing decision is “imminent” for Sarepta’s Duchenne drug eteplirsen

http://endpts.com/third-time-the-charm-analyst-says-a-marketing-decision-is-imminent-for-sareptas-duchenne-drug-eteplirsen/

“We believe that right now, someone, whether at Sarepta or the FDA, is looking at baseline and 48-week Western blots for 13 PROMOVI patients,” Skorney noted. “At this point, we think the decision should be pretty cut and dry: if the baseline blots show no band, and the vast majority of the 48-week blots show a (dystrophin) band, we predict a rapid accelerated approval for eteplirsen.”